↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
argenx moves on Forte's CD122 asset with direct tender, signaling pipeline urgency and willingness to absorb pre-data risk.
$47 million
after eighteen months of corridor pricing
$18.3 million
in the trailing twelve months and held
$22 million
cash as of the most recent filing
$1.80
the day before the announcement
argenx commenced a tender offer for Forte Biosciences, a clinical-stage company whose sole meaningful asset is FB102, a proprietary anti-CD122 monoclonal antibody. The offer opened this week. No dollar figure disclosed yet, but Forte's enterprise value sits near $47 million after eighteen months of corridor pricing. argenx typically moves when it sees clear mechanistic differentiation in early immunology.
Forte's FB102 targets CD122, the beta subunit of the interleukin-2 and interleukin-15 receptor. The antibody is in Phase 2 trials for moderate-to-severe atopic dermatitis and remains uncommitted to a lead indication. Forte burned through $18.3 million in the trailing twelve months and held $22 million cash as of the most recent filing. The runway was short. argenx's tender bypasses the usual merger agreement structure, suggesting either competing interest or a desire to avoid drawn-out board negotiations. Forte's stock traded below $1.80 the day before the announcement, well under its $11.40 debut price in 2020.
The acquisition logic is narrow but defensible. argenx built its franchise on neonatal Fc receptor antagonism with efgartigimod, which crossed $600 million in annualized revenue this quarter. The company has been explicit about pursuing complementary mechanisms in autoimmune and inflammatory disease, particularly where antibody depletion or T-cell modulation can serve overlapping patient populations. CD122 blockade suppresses regulatory T-cells and effector memory populations without full lymphodepletion. If FB102 proves synergistic with efgartigimod in skin or systemic autoimmune conditions, argenx gains optionality across its existing commercial infrastructure. If it does not, the writedown is containable.
What allocators should watch: the tender period typically closes within 20 to 25 business days unless extended. argenx will file the offer documents with the SEC within 72 hours of commencement, revealing price per share and any conditions precedent. Watch for competing bids from mid-tier dermatology specialists or Asian pharma with autoimmune pipelines. Forte's Phase 2 readout in atopic dermatitis is expected in the second half of 2025; if argenx closes before data, it signals confidence in earlier interim signals. Also monitor whether argenx retains Forte's Richmond, California site or folds the program into its Belgium or Boston operations.
The tender structure suggests argenx wanted speed over consensus. Forte's board likely had little leverage and shorter runway than the market assumed.
Branded by POPS4 · proof in 60 seconds
For the principal
Track tender close date and competing bids; argenx's M&A tempo suggests pipeline acceleration into autoimmune expansion.
For the operator
Watch SEC filings for price and conditionality; Forte's Phase 2 timing determines whether argenx buys data or buys mechanism.
For the house
No position in either name; note argenx as potential add on efgartigimod momentum if FB102 synergy proves out post-close.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.